Abstract
Background A better understanding of real-world clinical and economic outcomes associated with orthopedic sutures used for rotator cuff repair is needed.
Research Design and Methods A retrospective, descriptive cohort study using Premier Healthcare Database hospital-based data evaluated patients treated with Dynacord™ or FiberWire® for rotator cuff repair between January 2017-February 2022. Baseline patient characteristics and twelve-month outcomes were assessed. Each suture cohort was analyzed separately. No comparative analyses were performed in this study.
Results Baseline demographics of 1 074 patients treated with Dynacord™ and 19 899 treated with FiberWire®, respectively, were mean age 59.4, 59.9 years; 59.4% and 58.5% male. All-cause twelve-month hospital revisits were observed in 31.4% and 42.4%, and the incidence proportion with shoulder-related hospital revisits was 12.6% and 14.0%, respectively. The incidence of twelve-month rotator cuff re-repair was 1.2% for Dynacord™ and 1.8% for FiberWire®. Dynacord™ twelve-month all-cause revisit costs (standard deviation [SD]) were $1 649 ($5 870) and $2 230 ($7 204) for FiberWire®. Twelve-month complications, device removals, and manipulations were ≤1% for both cohorts.
Conclusions This study contributes clinical and economic real-world evidence on two types of orthopedic sutures used for rotator cuff repair.
Competing Interest Statement
All authors were employees or contractors of Johnson & Johnson at time of the study. Authors K.Corso, C.Smith, B.Varughese, and J. Ruppenkamp are currently employees of Johnson & Johnson.
Funding Statement
The study was funded by Johnson and Johnson, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of New England Institutional Review Board waived ethical approval for this work because the study does not involve human subjects research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: The study was funded by Johnson and Johnson, Inc.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
